Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators due to which they could serve as lead molecule for drug development. Development of HDAC based therapeutics is correlated to the development of HDAC inhibitors which have capacity to inhibit HDACs which have gone under abnormal changes. Some of the HDAC inhibitors has been successfully commercialized in global market for different ailments.
HDAC inhibitors are being developed for different malignancies and some of these products have been in global market for more than decade. New products for different diseases are being introduced in market. Most of them have been developed for oncological application while few products have been introduced in neurology category. Investigational HDAC inhibitors are being developed for HIV, autoimmune, inflammatory disease and other ailments. Potential of HDAC inhibitors in animal models for inflammatory bowel diseases, diabetes, multiple sclerosis, age-related macular degeneration, cardiovascular diseases and other diseases have been shown. HDAC inhibitors clinical pipeline is becoming strong as investment in their research and development is increasing. Various products are at different stages of clinical trials which would be introduced in coming years.
HDAC inhibitor market for cancer treatment for hematological malignancies and that to for lymphoma is quite competitive. Besides, Vorinostat and Istodax there is another drug for lymphoma called Beleodaq is available in this segment. Beleodaq is a novel pan HDAC inhibitor for treatment of fast-growing type of Non-Hodgkin Lymphoma (NHL)and Peripheral T-Cell Lymphoma (PTCL). It is expected that due to similar mechanism they will offer competition to each other in coming years. Competition is also expected to be offered by monoclonal antibodies which are already known for their superior pharmacological efficacy. In this scenario, HDAC inhibitor developers have to improve drug design and pharmacological profiles in order to survive in this market segment. Their costs are somewhat lesser then monoclonal antibodies due to which patients belonging to different financial background are expected to choose them as part of their therapeutic regime.
Novel HDAC inhibitors are also being discovered by investigators but their pharmacological and commercialization potential remains elusive. Some of them are already established in global market and others are being revisited for their therapeutics efficacy in other disease segments. Hydroxamates are one of the largest segment of HDAC inhibitors which have made their niche in cancer market segment. Other categories are also being developed for different ailments due to their role in blocking different HDAC members. It could be observed that they belong to different biological groups like aliphatic acids and cyclopeptides. On the other hand, synthetic derivatives are also available which could be easily modified by chemical processes. This fact shows that investigators have plethora of choices that will help them in development of suitable pharmaceutical product having high commercialization potential. However, lots of work is required in this segment for occupying major market shares and competing with previously available therapeutics.
\"Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015\" Report Highlights: